**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63107

**Manuscript Type:** MINIREVIEWS

**Burden of venous thromboembolism in patients with pancreatic cancer**

Frere C. Venous thromboembolism and pancreatic cancer

Corinne Frere

**Corinne Frere,** Department of Haematology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris F-75013, France

**Corinne Frere,** INSERM UMRS\_1166, Institute of Cardiometabolism And Nutrition, GRC 27 GRECO, Sorbonne Université, Paris F-75013, France

**Corinne Frere,** Groupe Francophone Thrombose et Cancer, Saint-Louis Hospital, Paris F-75010, France

**Author contributions:** Frere C performed the literature review and drafted the manuscript.

**Corresponding author: Corinne Frere, MD, PhD, Assistant Professor,** Department of Haematology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, Paris F-75013, France. corinne.frere@aphp.fr

**Received:** January 24, 2021

**Revised:** February 28, 2021

**Accepted:** April 22, 2021

**Published online:** May 21, 2021

**Abstract**

Pancreatic cancer (PC) is a devastatingmalignancy with fewer than 10% of patients being alive at 5 years after diagnosis. Venous thromboembolism (VTE) occurs in approximatively 20% of patients with PC, resulting in increased morbidity, mortality and significant health care costs. The management of VTE is particularly challenging in these frail patients. Adequate selection of the most appropriate anticoagulant for each individual patient according to the current international guidelines is warranted for overcoming treatment challenges. The International Initiative on Thrombosis and Cancer multi-language web-based mobile application (downloadable for free at www.itaccme.com) has been developed to help clinicians in decision making in the most complex situations. In this narrative review, we will discuss the contemporary epidemiology and burden of VTE in PC patients, the performances and limitations of current risk assessment models to predict the risk of VTE, as well as evidence from recent clinical trials for the primary prophylaxis and treatment of cancer-associated VTE that support up-dated clinical practice guidelines.

**Key Words:** Pancreatic cancer; Venous thromboembolism; Low-molecular weight heparin; Direct oral anticoagulant; Multi-language mobile application; Risk-assessment models; Thromboprophylaxis

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Frere C. Burden of venous thromboembolism in patients with pancreatic cancer. *World J Gastroenterol* 2021; 27(19): 2325-2340

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i19/2325.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i19.2325

**Core Tip:** Venous thromboembolism (VTE) is a common but potentially life-threatening complication in patients with Pancreatic cancer (PC). There is an urgent need to raise awareness on this underrecognized issue. This review discusses the incidence and risk factors of VTE in PC patients, and the results from recent clinical trials for the primary prophylaxis and treatment of VTE in cancer patients supporting the most recent clinical practice guidelines.

**INTRODUCTION**

Pancreatic cancer (PC) is a devastating disease with fewer than 10% of patients being alive at 5 years[1]. Its prevalence continues to increase worldwide[2]. In most cases, there is no effective treatment. Given its dismal prognosis[3], there is an urgent need to improve patient quality of life by integrating best supportive care[4,5].

Venous thromboembolism (VTE) is a frequent but still underrecognized complication in PC patients[6]. According to a recent large population-based cohort study[7], the incidence of PC-associated VTE has doubled from 1997 to 2017, due to increase in PC prevalence, improved survival, advanced age of PC patients, and better detection of incidental VTE with the routine use of computed tomography scans. Primary thromboprophylaxis is a supportive care with a well-documented clinical benefit, which remains unfortunately underused nowadays. Since 2013, the International Initiative on Thrombosis and Cancer (ITAC), a multidisciplinary group of experts from across the globe committed to improve the management of patients with cancer-associated thrombosis through dissemination of educational initiatives to health professionals, strives to raise awareness on this important issue[8].

Anticoagulation therapy is the mainstay of the VTE prevention and treatment, but its management is particularly challenging for the treating physicians in these patients who already suffer from multiple co-morbidities such as renal failure, hepatic failure, thrombocytopenia, and who undergo complex cancer treatment protocols[9,10].

Herein, we discuss the most recent data on the incidence and risk factors of VTE in PC patients, as well as evidence from recent clinical trials of low-molecular-weight heparin (LMWH) and direct oral anticoagulants (DOAC) for the primary prophylaxis and treatment of cancer-associated VTE that support current clinical practices guidelines (CPGs)[8,11,12].

**EPIDEMIOLOGY OF VTE IN PC AND IMPACT ON SURVIVAL**

Cancer has been demonstrated to be an independent major risk factor for VTE[13]. The extent of this risk mainly depends on cancer type and disease stage. Among all cancer types, PC carries the highest risk for VTE[7,14]. In retrospective cohorts of PC patients, the reported incidence of VTE varies broadly from 5% to 57%[15-33], depending on the study population, the duration of follow-up, the definition of VTE and the methods used for diagnosing VTE.

Due to their large sample sizes, multicenter prospective design, and systematic follow-up, phase 3 randomized control trials (RCTs) conducted in PC patients are expected to provide reliable data on the true incidence of VTE. However, a recent systematic review and meta-analysis of chemotherapeutic and thromboprophylaxis RCTs conducted in PC patients highlighted that VTE events were underreported in chemotherapeutic RCTs[6]. The pooled rate of VTE in chemotherapy studies (*n* = 13, 5694 patients) was 5.9% [95% confidence interval (CI): 3.9-9.0; *I²* = 94%] and significantly lower than the corresponding 16.5% (95%CI: 11.7-23.3; *P* < 0.001) reported in thromboprophylaxis studies (*n* = 9, 631 patients, *I²* = 69%). Importantly, 30 eligible chemotherapy RCTs (*n* = 9000 patients) were excluded from this meta-analysis because they did not report VTE as adverse events[6], which reveals quite clearly a lack of awareness on the burden of VTE among oncologists.

The incidence and risk factors for VTE was recently assessed in a large prospective multicenter cohort of patients with newly diagnosed PC[34], providing real-life contemporary estimates. In this study, 152 out of 731 (20.79%) patients developed a VTE event, with a median time from PC diagnosis to VTE of 4 mo. In competing-risk analysis, the cumulative rates of VTE were approximatively 13% and 20% at 6 mo and 1 year, respectively[34].

The most common VTE events occurring in PC patients are deep vein thrombosis (DVT) and pulmonary embolism (PE)[35], but incidental PE and incidental visceral vein thrombosis (VVT) are increasingly diagnosed, accounting now for approximatively 50% of all reported VTE events[23,30,34,36]. In the BACAP-VTE study[34], DVT, PE, VVT, and combined events were observed in 26%, 17%, 30% and 21% of patients, respectively. Overall, 46% of VTE events were symptomatic and 54% of them were asymptomatic[34].

Early retrospective studies reported no association between VTE and overall survival (OS) in PC patients[21,27]. However, all patients included in these studies had metastatic disease with a short life expectancy. By contrast, later studies reported that the onset of VTE was associated with a poorer prognosis. In a retrospective cohort of 227 patients with unresectable PC, VTE during the course of chemotherapy was associated with a 2.5-fold decrease in progression-free survival (PFS) and a 1.6-fold risk decrease in OS[17]. Similarly, in a small cohort of 135 PC patients, the onset of VTE was significantly associated with increased mortality[23]. Importantly, survival was significantly improved in patients with VTE receiving anticoagulant therapy compared to those who did not receive anticoagulant therapy [hazard ratio (HR) 0.30, 95%CI: 0.12-0.74, *P* = 0.009][23]. Retrospective studies focusing on incidental VTE in PC patients also reported an association between VVT and mortality[36,37]. Similarly, in a prospective cohort of 731 newly diagnosed PC, patients who developed asymptomatic or symptomatic VTE during follow-up had significantly shorter PFS (HR 1.74; 95%CI: 1.19-2.54; *P* = 0.004) and OS (HR 2.02; 95%CI: 1.57-2.60; *P* < 0.001) compared to those who did not developed VTE[34].

**RISK FACTORS FOR VTE AND RISK STRATIFICATION IN PC PATIENTS**

Several studies have demonstrated that the most important risk factor for VTE in PC patients is the presence of a metastatic disease[16,18,27,31,34,38,39]. In a recent retrospective cohort of 165 PC patients, metastatic disease was associated with a 4.8-fold increase in the risk for VTE; 41 out of 51 patients who developed VTE had metastasis at diagnosis[39]. Similarly, in the BACAP-VTE study[34], metastatic tumors were associated with a 2.5-fold increased risk for VTE compared to non-metastatic tumors.

Major abdominal surgery is also an important risk factor for VTE in PC patients. In an early observational study of 1915 patients with exocrine PC, 127 out of 383 (33.1%) patients requiring pancreatic surgery developed postsurgical VTE[22]. Similarly, 31 out of 209 (14.8%) patients requiring pancreatic surgery developed postsurgical VTE in a large retrospective study of 1,115 conducted in East Asian population[27].

Chemotherapy increases the risk of VTE in cancer patients[40]. Nevertheless, as recently highlighted by Chiasakul *et al*[6], the rates of VTE were underreported in PC chemotherapy RCTs and data on the respective risk of various chemotherapy regimens remain scarce. In recent retrospective or prospective cohorts of PC patients, the rate of VTE did not differ between those receiving gemcitabine-based chemotherapy and those receiving FOLFIRINOX[30,34]. In the subgroup of 273 PC patients included in the CASSINI trial[41], the rates of VTE did not differ between patients treated with 5-fluorouracil-based regimen *vs* gemcitabine-based regimen.

Systematic screening of VTE is not recommended in daily clinical practice. However, all PC patients should receive verbal and written information on the risk factors for VTE, as well as on the signs and symptoms of VTE to promote self-diagnosis and reporting of VTE symptoms.

Over the past ten years, many efforts have been made to develop risk assessment models (RAM) aiming to select cancer patients at highest risk for VTE, and therefore expected to have the best benefit from thromboprophylaxis. However, none of these RAM was designed to specifically assess this risk in PC patients.

The Caprini score is the most widely RAM to assess the risk of VTE in patients undergoing surgery. It has been validated in several types of cancers[42]. However, this model was unable to identify patients at highest risk for VTE in a retrospective cohort of 426 PC patients undergoing preoperative treatment followed by surgical resection[43].

Furthermore, the Khorana score[44] is the most widely used RAM to assess the risk of VTE in ambulatory cancer patients. It was developed ten years ago[44]. It assigns 1 to 2 points to 5 simple clinical and laboratory variables (primary tumor site, platelet count ≥ 350 × 109/L, hemoglobin concentration ≤ 10 g/dL or use of erythropoiesis-stimulating agents, leukocyte count ≥ 11 × 109/L, body mass index (BMI) ≥ 35 kg/m2. Patients are classified as being at “low-risk” (Khorana score = 0), “intermediate-risk” (Khorana score = 1-2), or “high-risk” (Khorana score ≥ 3). All PC patients are classified as being at intermediate- or high-risk. Unfortunately, this model did not discriminate between these two risk categories, neither in retrospective studies of PC patients undergoing chemotherapy[25,28-30,32,39,45], nor in the large prospective BACAP-VTE study[34], nor in the subgroup of 273 PC patients included in the recent CASSINI trial[41] (Table 1), questioning its relevance in this specific population.

Several modifications to this RAM by the addition of other variables to the model have been proposed. The PROTECHT score[46], which includes treatment with cisplatin or carboplatin-based chemotherapy or gemcitabine was found to perform better than the Khorana score in a retrospective analysis of the PROTECHT study, decreasing the number needed to treat (NTT) from 50 to 17. However, this score has not been externally validated in PC patients. More recently, the ONKOTEV score[47] was developed in a prospective cohort of 843 various cancers patients in Italy and Germany, including 253 patient with gastroenteric cancer. The ONKOTEV score assigns one point to four variables, namely: a Khorana score > 2, a history of previous VTE, a metastatic disease, and a compression of vascular structures by the tumor. The ONKOTEV score demonstrated a significantly higher predictive power compared to the Khorana score in the original development cohort and was recently externally validated in a retrospective single-center cohort of 165 PC patients treated in Portugal with promising results[39]. Ninety-two (55.8%) patients had a metastatic disease at diagnosis and 109 (66.1%) received systemic chemotherapy. At inclusion, 18.2% of patients had an ONKOTEV score of 0, 38.2% of patients had an ONKOTEV score of 1, 33.3% of patients had an ONKOTEV score of 2, and 10.3% of patients had an ONKOTEV score > 2. During a median observation period of 6.3 mo, 51 out 165 (30.9%) PC patients developed VTE. The cumulative incidence of VTE was 82.4% in patients with an ONKOTEV > 2 compared to 3.3% in those with an ONKOTEV score of 0[39]. These results suggest that the ONKOTEV score could be of help to better stratify PC patients having the highest risk for VTE but deserve further confirmation in prospective cohorts of ambulatory PC patients.

Integration of relevant biomarkers into current RAMs might improve their ability to predict VTE. Faille *et al*[38] recently assessed the diagnosis performances of several biomarkers to predict VTE in a prospective cohort of 50 PC patients, including Factor VIII, D-dimers, von Willebrand factor, free tissue factor pathway inhibitor, micro-vesicle-tissue factor (MV-TF) activity and CA 19.9. In multivariate analysis, baseline D-dimers ≥ 2.16 μg/mL (HR 4.9; 95%CI: 1.0-23.1), baseline MV-TF activity 2.37 pg/mL (HR 10.5; 95%CI: 1.5-72.4), and baseline CA 19.9 ≥ 2153 U/mL (HR 9.5; 95%CI: 1.5-60.2) were significantly associated with VTE after adjustment for age and sex, with the best sensitivity and specificity in predicting VTE obtained for CA 19-9[38]. However, these associations were no more significant after adjustment for the presence of metastasis, suggesting once again that the presence of a metastatic disease is the most important risk factor for VTE in PC patients.

The clinical-genetic Thrombo inCode-Oncology (TiC-Onco) score was developed in a prospective cohort of 391 ambulatory patients with various cancers initiating systemic chemotherapy, including 72 (18.5%) patients with PC[48]. Seventy-one out of 391 (18%) patients developed VTE within 6 mo. The prespecified variable selection process selected both clinical variables (tumor site, family history of VTE, BMI ≥ 25 kg/m2) and genetic variables (germline polymorphisms in the *F5*, *F13* and *SERPINA10* genes) for inclusion in the score. In the derivation cohort, the TiC-Onco score performed better than the Khorana score in predicting VTE at 6 mo (sensitivity 49% *vs* 22%, specificity 81% *vs* 82%, positive predictive value 37% *vs* 22%, and negative predictive value 88% *vs* 82%)[48]. Importantly, patients suffering from PC had higher rates of VTE (40%) than patients with other type of cancers (18%), suggesting that PC has a major impact on the accuracy of the TiC-Onco score. However, this model has not yet been externally validated in a cohort of PC patients.

The CATS/MICA score[49] includes two variables, namely: tumour-site risk category (very high *vs* high and high *vs* low or intermediate) and continuous D-dimer levels. It was developed in the prospective Vienna Cancer and Thrombosis Study (CATS) cohort of 1423 ambulatory cancer patients undergoing chemotherapy, including 118 (8%) patients with PC[49]. During a median follow-up of 6 mo, 80 out of 1423 patients (6%) developed VTE. In the CATS cohort, the C-index of the model was 0.66 (95%CI: 0.63-0.67) compared to 0.61 (95%CI: 0.51-0.70) for the Khorana score[49]. The score was then validated in the prospective Multinational Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism (MICA) cohort (*n* = 832), including 116 (14%) patients with PC[49]. Using this RAM, all PC patients are classified at intermediate or high risk of VTE. Of note, the CATS/MICA score has not yet been externally validated in a cohort of PC patients.

Finally, machine learning methods are increasingly used for the development of prediction models. Two recent studies conducted in various cancer patients[50] or in ovarian cancer patients[51] have demonstrated that such models could improve the prediction of VTE compared to conventional methods.

**WHEN SHOULD WE CONSIDER PRIMARY PROPHYLAXIS IN PC PATIENTS?**

***Surgical PC patients***

Prolonged thromboprophylaxis following major abdominal surgery has been shown to decrease the rate of VTE by approximately 50%[52]. Accordingly, all current CPGs recommend using thromboprophylaxis in surgical PC patients[8,11]. In those undergoing laparotomy or laparoscopic surgery without contraindications to LMWH, the highest LMWH prophylactic dose should be used for an extended duration of 4 wk (Grade 1A)[8]. External compression devices alone should be used only in patients with contraindications to anticoagulants (Grade 2B)[8]. Inferior vena cava filters should not be used systematically in this setting (Grade 1A)[8]. The risks of VTE should be balanced by the competing risk of bleeding. Numerous factors such as advanced or metastatic disease, older age, anemia, thrombocytopenia, renal impairment, liver dysfunction, and concomitant anticancer therapies may potentiate the overall bleeding risk and should be taken into account. The careful evaluation of each individual profile is warranted for overcoming management challenges.

***Hospitalized PC patients***

Acute medical illness and bed rest constitute transient factors increasing the risk of VTE in hospitalized cancer patients. Although there is no large RCT specifically demonstrating the benefit of thromboprophylaxis in cancer inpatients, RCTs conducted in non-cancer inpatients have demonstrated that LMWH improves survival and reduces VTE in general medical patients hospitalized with acute medical conditions, and recommendations for cancer patients have been extrapolated from these RCTs. The ITAC CPGs[8] recommend using LMWH at prophylactic doses or unfractionated heparin (UFH) or Fondaparinux in PC inpatients without contraindications to anticoagulants (Grade 1B)[8]. Due to the lack of data on the efficacy and safety of DOAC in this setting, they should not be used (Best clinical practice)[8].

***Ambulatory PC patients***

Most cancer patients develop VTE in the outpatient setting[53]. The net clinical benefit of primary thromboprophylaxis in advanced PC patients has been firmly established in two pivotal RCTs[54,55] which specifically addressed the efficacy and safety of LMWH in this setting(Table 2). Based on the results of these two trials, the ITAC CPGs recommend using primary thromboprophylaxis with LMWH in ambulatory advanced PC patients receiving chemotherapy with a Grade 1B evidence level since 2013[8,56,57].

The FRAGEM trial randomized 123 advanced PC patients to receive gemcitabine plus weight-adjusted therapeutic doses of dalteparin for 12 wk or gemcitabine alone[54]. The coprimary endpoints were the rate of symptomatic or incidentally diagnosed VTE events during the 12-wk anticoagulation period and the rate of symptomatic or incidentally diagnosed VTE events during the overall follow-up period. The rate of VTE was significantly lower in the dalteparin arm (3.4% *vs* 23% in the control arm, risk ratio 0.145, 95%CI: 0.035-0.612, *P* = 0.002), resulting in a NNT of 6 patients to prevent 1 VTE event. No VTE-related deaths occurred in the dalteparin arm compared to 5 (8.3%) VTE-related deaths in the control arm. The rates of major bleeding did not differ between the 2 arms and were lower than 3%, with only 2 patients experiencing a major bleeding requiring anticoagulation discontinuation. Of note, patients in the dalteparin arm experienced more minor bleeding such as skin bruising or epistaxis (9% *vs* 3% in the gemcitabine alone arm)[54]. There was no difference in PFS or OS between the two arms.

The PROSPECT-CONKO 004 trial randomized 312 advanced PC patients to receive supra-prophylactic doses of enoxaparin during the first 3 mo of chemotherapy or chemotherapy alone[55]. Unlike in FRAGEM, incidental VTE events were excluded from the analysis. The cumulative incidence rate of symptomatic VTE within the first 3 mo was 1.3% in the enoxaparin arm compared to 10.2% in the control arm (HR 0.12, 95%CI: 0.03-0.52), resulting in a NNT of 11 patients to prevent 1 VTE event. The rates of major bleeding events were similar in both arms. PFS and OS did not differ between the 2 arms[55].

Two additional phase III double-blinded placebo-controlled trials (the PROTECHT[58] and the SAVE-ONCO studies[59]) evaluated the efficacy and safety of primary thromboprophylaxis with prophylactic doses of other LMWH in ambulatory cancer patients receiving chemotherapy. In the PROTECHT study (*n* = 1150)[58], while nadroparin reduced the rate of VTE from 3.9% to 2.0% (*P* = 0.02) without difference in major bleeding in the overall population, the rates of VTE did not differ between the two arms in the subgroup of 53 PC patients (*P* = 0.755). In the SAVE-ONCO study (*n* = 3221)[59] the rate of VTE was 1.2% in the semuloparin arm compared to 3.4% in the placebo arm (HR 0.36, 95%CI: 0.21-0.60; *P* < 0.001) in the overall population, without difference in major bleeding (HR 1.05, 95%CI: 0.55-1.99). The absolute VTE risk reduction with semuloparin appeared to be much higher in the subgroup of 254 PC patients. The magnitude of the VTE risk reduction was similar to that obtained with therapeutic doses of dalteparin in the FRAGEM study[54] or with supra-prophylactic doses of enoxaparin in the PROSPECT-CONKO 004 study[55].

More recently, two randomized placebo-controlled trials assessed the efficacy and safety of primary thromboprophylaxis with prophylactic doses of DOACs (apixaban 2.5 mg twice daily for up to 6 mo in the AVERT trial[60]; rivaroxaban 10 mg once daily for up to 6 mo in the CASSINI trial[61]) in cancer patients with a Khorana score ≥ 2 undergoing chemotherapy. Results from a subgroup of PC patients were reported only for the CASSINI trial[41]. Among the 273 PC patients included in this prespecified subgroup analysis, 214 (78%) had a locally advanced or metastatic PC and 271 (99.3%) were receiving cytotoxic chemotherapy (fluorouracil-based in 47.6% of cases and gemcitabine-based in 44.7% of cases). Rivaroxaban did not significantly reduce the rates of the primary efficacy endpoint of symptomatic DVT, asymptomatic proximal DVT, any PE and VTE-related death within the 6 mo observation period (absolute difference of 3.4%, *P* = not significant). However, most of VTE events occurred after discontinuation of rivaroxaban (61.5%) compared to placebo (22.2%). During the intervention period, rivaroxaban significantly reduced the rates of the primary efficacy endpoint from 10.1% to 3.7% (absolute difference of 6.4%, HR 0.35, 95%CI: 0.13-0.97, *P* = 0.034), resulting in a NTT of 16 patients to prevent 1 event. Importantly, 2 out of 5 events in the rivaroxaban arm and 5 out of 14 events in the placebo arm were asymptomatic lower-extremity proximal DVT diagnosed by ultrasound screening during the follow-up, leading to overestimate the rates of VTE in both arms. The rates of major bleeding and all-cause mortality did not differ between the two arms[41].

Recently, a systematic review and meta-analysis aggregated the data from the 1003 PC patients enrolled in the 5 above-mentioned RCTs[62]. Primary thromboprophylaxis was estimated to significantly reduce the risk of symptomatic VTE by approximately 69%, resulting in a NTT of 11.9 to prevent one VTE event, without increase in the risk of major bleeding. Sensitivity analyzes showed that primary prophylaxis with LMWH or DOAC, and prophylactic doses or supra-prophylactic doses of anticoagulants reduced the risk of VTE with the same magnitude.

In light of the results from the AVERT and CASSINI trials, the ITAC[8] and ASCO[11] CPGs now recommend thromboprophylaxis with apixaban or rivaroxaban in cancer outpatients undergoing chemotherapy having a Khorana score ≥ 2, no bleeding risk and no drug-drug interactions (Grade 1B)[8]. Since the Khorana score assigns + 2 points for PC, thromboprophylaxis with DOAC or LMWH may be now offered in all ambulatory PC patients. Decisions to initiate thromboprophylaxis should be made based on a multidisciplinary patient-centered approach, after close discussion with the patient.

Nevertheless, primary thromboprophylaxis has not been yet widely adopted in PC outpatients, mainly due to fear of bleeding in otherwise frail subjects and inherent costs for such therapy.

**HOW TO TREAT VTE IN PC PATIENTS?**

***A step-based adapted approach***

For many years, monotherapy with LMWH has been the standard of care to treat cancer-associated VTE, based on the results of 5 landmark RCTs comparing LMWH to vitamin K antagonists[63-67]. However, positive results from 4 recent RCTs comparing DOAC to LMWH monotherapy for the treatment of cancer-associated thrombosis[68-71] (Table 3) prompted current updated CPGs to include DOACs as a new first-line option in selected patients, but not all[8,11].

The ability to now use oral-only anticoagulation strategies, precluding the need for long-term daily injection and dose adjustment, may seem appealing but adds to the complexity of decision making. Appropriate selection of anticoagulants appears more than ever as a critical element of high-quality care for cancer patients with VTE, and numerous factors must be taken into consideration when choosing one anticoagulant rather than the other[72]. A personalized approach is warranted.

The ITAC CPGs recommend using LMWH for the initial and long-term treatment of established VTE when creatinine clearance is ≥ 30 mL per min (Grade 1B)[8]. For patients without risk of gastrointestinal or genitourinary bleeding, rivaroxaban (in the first 10 d) or edoxaban (started after at least 5 d of parenteral anticoagulation) can also be used (Grade 1B)[8]. UFH provides an alternative option when LMWH or DOACs are contraindicated, or not available (Grade 2C)[8]. Anticoagulation should be continued for at least 6 mo (Grade 1A) or indefinitely while cancer is active or treated[8].

LMWH are the preferred option in patients with VVT due their short half-life and possible dose reduction in case of esophageal varices.

Briefly, DOAC are a reasonable option in ambulatory PC patients with DVT or PE with an intact upper gastrointestinal tract, without nausea or vomiting, with a low risk of bleeding, with a platelet count > 50000/mm3, with a creatinine clearance > 30 mL/min, without severe hepatic impairment and for whom no surgical intervention is planned. They should not be used in patients with creatinine clearance < 30 mL/min, luminal gastrointestinal lesion, platelet count < 50000/mm3, high bleeding risk, recent or planned surgery, or potential drug-drug interactions[73,74].

A step-based adapted approach (Figure 1), incorporating tumor type, careful examination of bleeding risk, potential drug–drug interactions, and patient preferences, has been proposed by several authors[73,74]. The multi-language web-based mobile application developed by the ITAC (downloadable for free at www.itaccme.com) based on such decision-tree algorithms is paramount to help clinicians in decision making[8].

Patients should be actively involved in treatment decisions and those treated with anticoagulants should be educated on the rationale for their treatment, the potential treatment safety concerns, and the risk of drug-drug interactions to ensure optimal adherence and treatment outcomes.

Incidental VTE is associated with high risks of recurrent VTE and VTE-related mortality[75-77] and should be treated as symptomatic VTE[8].

**CONCLUSION**

VTE is a common and potentially life-threatening complication in PC patients. Strict adherence to current evidence-based guidelines and dedicated patient education programs are warranted to optimize both the primary thromboprophylaxis and the treatment of VTE in PC patients. Clinical innovative tools, such as the multi-language web-based mobile application developed by the ITAC (downloadable for free at www.itaccme.com) will be paramount to assist clinicians in rigorously implementing updated CPGs and further decrease the burden of VTE in PC patients.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

2 **Rahib L**, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155]

3 **Lambert A**, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. *Ther Adv Med Oncol* 2019; **11**: 1758835919875568 [PMID: 31598142 DOI: 10.1177/1758835919875568]

4 **Moffat GT**, Epstein AS, O'Reilly EM. Pancreatic cancer-A disease in need: Optimizing and integrating supportive care. *Cancer* 2019; **125**: 3927-3935 [PMID: 31381149 DOI: 10.1002/cncr.32423]

5 **Farge D**, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. *Cancers (Basel)* 2020; **12** [PMID: 32155940 DOI: 10.3390/cancers12030618]

6 **Chiasakul T**, Patell R, Maraveyas A, Carrier M, Zwicker JI. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis *vs* chemotherapeutic trials. *J Thromb Haemost* 2021; **19**: 489-501 [PMID: 33174368 DOI: 10.1111/jth.15175]

7 **Mulder FI**, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, Büller HR, Sørensen HT. Venous thromboembolism in cancer patients: a population-based cohort study. *Blood* 2021; **137**: 1959-1969 [PMID: 33171494 DOI: 10.1182/blood.2020007338]

8 **Farge D**, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol* 2019; **20**: e566-e581 [PMID: 31492632 DOI: 10.1016/S1470-2045(19)30336-5]

9 **Prandoni P**, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood* 2002; **100**: 3484-3488 [PMID: 12393647 DOI: 10.1182/blood-2002-01-0108]

10 **Abdulla A**, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer. *Thromb Haemost* 2020; **120**: 702-713 [PMID: 32289865 DOI: 10.1055/s-0040-1708481]

11 **Key NS**, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol* 2020; **38**: 496-520 [PMID: 31381464 DOI: 10.1200/JCO.19.01461]

12 **National Comprehensive Cancer Network**. NCCN guideline on cancer‐associated venous thromboembolic disease. Version 1. 2020. [cited 3 January 2021]. In: National Comprehensive Cancer Network [Internet]. Available from: https://www.nccn.org/professionals/physician\_gls/pdf/vte.pdf

13 **Levitan N**, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy *vs* those without malignancy. Risk analysis using Medicare claims data. *Medicine (Baltimore)* 1999; **78**: 285-291

14 **Horsted F**, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *PLoS Med* 2012; **9**: e1001275 [PMID: 22859911 DOI: 10.1371/journal.pmed.1001275]

15 **Sproul EE**. Carcinoma and Venous Thrombosis: The Frequency of Association of Carcinoma in the Body or Tail of the Pancreas with Multiple Venous Thrombosis. *Am J Cancer* 1938; **34**: 566-585

16 **Blom JW**, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. *Eur J Cancer* 2006; **42**: 410-414 [PMID: 16321518 DOI: 10.1016/j.ejca.2005.09.013]

17 **Mandalà M**, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, Berardi R, Mosconi S, Torri V, Labianca R. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. *Ann Oncol* 2007; **18**: 1660-1665 [PMID: 17660490 DOI: 10.1093/annonc/mdm284]

18 **Mitry E**, Taleb-Fayad R, Deschamps A, Mansencal N, Lepère C, Declety G, Lièvre A, Vaillant JN, Lesur G, Cramer E, Dubourg O, Rougier P. Risk of venous thrombosis in patients with pancreatic adenocarcinoma. *Gastroenterol Clin Biol* 2007; **31**: 1139-1142 [PMID: 18176374 DOI: 10.1016/s0399-8320(07)78352-5]

19 **Oh SY**, Kim JH, Lee KW, Bang SM, Hwang JH, Oh D, Lee JS. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. *Thromb Res* 2008; **122**: 485-490 [PMID: 18234292 DOI: 10.1016/j.thromres.2007.12.015]

20 **Poruk KE**, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 2605-2610 [PMID: 20729288 DOI: 10.1158/1055-9965.EPI-10-0178]

21 **Shaib W**, Deng Y, Zilterman D, Lundberg B, Saif MW. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. *Anticancer Res* 2010; **30**: 4261-4264 [PMID: 21036750]

22 **Epstein AS**, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O'Reilly EM. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. *Cancer* 2012; **118**: 3053-3061 [PMID: 21989534 DOI: 10.1002/cncr.26600]

23 **Menapace LA**, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. *Thromb Haemost* 2011; **106**: 371-378 [PMID: 21713322 DOI: 10.1160/TH10-12-0789]

24 **Afsar CU**, Gunaldi M, Kum P, Sahin B, Erkisi M, Kara IO, Paydas S, Duman BB, Ercolak V, Karaca F, Uyeturk U, Guner SI. Pancreatic carcinoma, thrombosis and mean platelet volume: single center experience from the southeast region of Turkey. *Asian Pac J Cancer Prev* 2014; **15**: 9143-9146 [PMID: 25422192 DOI: 10.7314/apjcp.2014.15.21.9143]

25 **Muñoz Martín AJ**, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. *Clin Transl Oncol* 2014; **16**: 927-930 [PMID: 24643701 DOI: 10.1007/s12094-014-1165-y]

26 **Krepline AN**, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? *J Surg Oncol* 2016; **114**: 581-586 [PMID: 27760280 DOI: 10.1002/jso.24361]

27 **Lee JC**, Ro YS, Cho J, Park Y, Lee JH, Hwang JH, Choi HJ, Lee S. Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study. *Medicine (Baltimore)* 2016; **95**: e3472 [PMID: 27124043 DOI: 10.1097/MD.0000000000003472]

28 **Kruger S**, Haas M, Burkl C, Goehring P, Kleespies A, Roeder F, Gallmeier E, Ormanns S, Westphalen CB, Heinemann V, Rank A, Boeck S. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. *Thromb Res* 2017; **157**: 9-15 [PMID: 28675831 DOI: 10.1016/j.thromres.2017.06.021]

29 **van Es N**, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. *Thromb Res* 2017; **150**: 30-32 [PMID: 28002757 DOI: 10.1016/j.thromres.2016.12.013]

30 **Berger AK**, Singh HM, Werft W, Muckenhuber A, Sprick MR, Trumpp A, Weichert W, Jäger D, Springfeld C. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. *Pancreatology* 2017; **17**: 629-634 [PMID: 28462862 DOI: 10.1016/j.pan.2017.04.012]

31 **Chen JS**, Hung CY, Chang H, Liu CT, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. *Cancers (Basel)* 2018; **10** [PMID: 30544670 DOI: 10.3390/cancers10120501]

32 **Kim JS**, Kang EJ, Kim DS, Choi YJ, Lee SY, Kim HJ, Seo HY, Kim JS. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study. *BMC Cancer* 2018; **18**: 1260 [PMID: 30558603 DOI: 10.1186/s12885-018-5154-3]

33 **Ouaissi M**, Frasconi C, Mege D, Panicot-Dubois L, Boiron L, Dahan L, Debourdeau P, Dubois C, Farge D, Sielezneff I. Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. *Hepatobiliary Pancreat Dis Int* 2015; **14**: 436-442 [PMID: 26256090 DOI: 10.1016/s1499-3872(15)60397-6]

34 **Frere C**, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D; BACAP Consortium. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. *Gastroenterology* 2020; **158**: 1346-1358.e4 [PMID: 31843588 DOI: 10.1053/j.gastro.2019.12.009]

35 **Khorana AA**, Fine RL. Pancreatic cancer and thromboembolic disease. *Lancet Oncol* 2004; **5**: 655-663 [PMID: 15522652 DOI: 10.1016/S1470-2045(04)01606-7]

36 **Mier-Hicks A**, Raj M, Do RK, Yu KH, Lowery MA, Varghese A, O'Reilly EM. Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. *Clin Colorectal Cancer* 2018; **17**: 121-128 [PMID: 29477452 DOI: 10.1016/j.clcc.2018.01.008]

37 **Afzal A**, Suhong L, Gage BF, Schoen MW, Carson K, Thomas T, Sanfilippo K. Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. *Thromb Res* 2020; **185**: 125-131 [PMID: 31812026 DOI: 10.1016/j.thromres.2019.11.023]

38 **Faille D**, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Lévy P, Ruszniewski P, Ajzenberg N, Rebours V. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. *Oncotarget* 2018; **9**: 26453-26465 [PMID: 29899870 DOI: 10.18632/oncotarget.25458]

39 **Godinho J**, Casa-Nova M, Moreira-Pinto J, Simões P, Paralta Branco F, Leal-Costa L, Faria A, Lopes F, Teixeira JA, Passos-Coelho JL. ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis. *Oncologist* 2020; **25**: e284-e290 [PMID: 32043787 DOI: 10.1634/theoncologist.2019-0510]

40 **Heit JA**. Epidemiology of venous thromboembolism. *Nat Rev Cardiol* 2015; **12**: 464-474 [PMID: 26076949 DOI: 10.1038/nrcardio.2015.83]

41 **Vadhan-Raj S**, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. *Cancer Med* 2020; **9**: 6196-6204 [PMID: 32663379 DOI: 10.1002/cam4.3269]

42 **Cronin M**, Dengler N, Krauss ES, Segal A, Wei N, Daly M, Mota F, Caprini JA. Completion of the Updated Caprini Risk Assessment Model (2013 Version). *Clin Appl Thromb Hemost* 2019; **25**: 1076029619838052 [PMID: 30939900 DOI: 10.1177/1076029619838052]

43 **Boone BA**, Zenati MS, Rieser C, Hamad A, Al-Abbas A, Zureikat AH, Hogg ME, Neal MD, Zeh HJ 3rd. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. *Ann Surg Oncol* 2019; **26**: 1503-1511 [PMID: 30652227 DOI: 10.1245/s10434-018-07148-z]

44 **Khorana AA**, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood* 2008; **111**: 4902-4907 [PMID: 18216292 DOI: 10.1182/blood-2007-10-116327]

45 **Pelzer U**, Sinn M, Stieler J, Riess H. [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. *Dtsch Med Wochenschr* 2013; **138**: 2084-2088 [PMID: 24085361 DOI: 10.1055/s-0033-1349608]

46 **Verso M**, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. *Intern Emerg Med* 2012; **7**: 291-292 [PMID: 22547369 DOI: 10.1007/s11739-012-0784-y]

47 **Cella CA**, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. *Oncologist* 2017; **22**: 601-608 [PMID: 28424324 DOI: 10.1634/theoncologist.2016-0246]

48 **Muñoz Martín AJ**, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, Salgado M, Martínez E, Calzas J, Rupérez A, Souto JC, Martín M, Salas E, Soria JM. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. *Br J Cancer* 2018; **118**: 1056-1061 [PMID: 29588512 DOI: 10.1038/s41416-018-0027-8]

49 **Pabinger I**, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, Büller HR, Ay C. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. *Lancet Haematol* 2018; **5**: e289-e298 [PMID: 29885940 DOI: 10.1016/S2352-3026(18)30063-2]

50 **Ferroni P**, Zanzotto FM, Scarpato N, Riondino S, Guadagni F, Roselli M. Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. *Dis Markers* 2017; **2017**: 8781379 [PMID: 29104344 DOI: 10.1155/2017/8781379]

51 **Fresard ME**, Erices R, Bravo ML, Cuello M, Owen GI, Ibanez C, Rodriguez-Fernandez M. Multi-Objective Optimization for Personalized Prediction of Venous Thromboembolism in Ovarian Cancer Patients. *IEEE J Biomed Health Inform* 2020; **24**: 1500-1508 [PMID: 31562113 DOI: 10.1109/JBHI.2019.2943499]

52 **Felder S**, Rasmussen MS, King R, Sklow B, Kwaan M, Madoff R, Jensen C. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. *Cochrane Database Syst Rev* 2019; **8**: CD004318 [PMID: 31449321 DOI: 10.1002/14651858.CD004318.pub5]

53 **Spencer FA**, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. *Arch Intern Med* 2007; **167**: 1471-1475 [PMID: 17646600 DOI: 10.1001/archinte.167.14.1471]

54 **Maraveyas A**, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine *vs* gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. *Eur J Cancer* 2012; **48**: 1283-1292 [PMID: 22100906 DOI: 10.1016/j.ejca.2011.10.017]

55 **Pelzer U**, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. *J Clin Oncol* 2015; **33**: 2028-2034 [PMID: 25987694 DOI: 10.1200/JCO.2014.55.1481]

56 **Farge D**, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *J Thromb Haemost* 2013; **11**: 56-70 [PMID: 23217107 DOI: 10.1111/jth.12070]

57 **Farge D**, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol* 2016; **17**: e452-e466 [PMID: 27733271 DOI: 10.1016/S1470-2045(16)30369-2]

58 **Agnelli G**, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol* 2009; **10**: 943-949 [PMID: 19726226 DOI: 10.1016/S1470-2045(09)70232-3]

59 **Agnelli G**, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *N Engl J Med* 2012; **366**: 601-609 [PMID: 22335737 DOI: 10.1056/NEJMoa1108898]

60 **Carrier M**, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. *N Engl J Med* 2019; **380**: 711-719 [PMID: 30511879 DOI: 10.1056/NEJMoa1814468]

61 **Khorana AA**, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. *N Engl J Med* 2019; **380**: 720-728 [PMID: 30786186 DOI: 10.1056/NEJMoa1814630]

62 **Frere C**, Crichi B, Bournet B, Canivet C, Abdallah NA, Buscail L, Farge D. Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Cancers (Basel)* 2020; **12** [PMID: 32722064 DOI: 10.3390/cancers12082028]

63 **Meyer G**, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med* 2002; **162**: 1729-1735 [PMID: 12153376 DOI: 10.1001/archinte.162.15.1729]

64 **Lee AY**, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin *vs* Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin *vs* a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med* 2003; **349**: 146-153 [PMID: 12853587 DOI: 10.1056/NEJMoa025313]

65 **Deitcher SR**, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone *vs* initial enoxaparin followed by warfarin for a 180-day period. *Clin Appl Thromb Hemost* 2006; **12**: 389-396 [PMID: 17000884 DOI: 10.1177/1076029606293692]

66 **Hull RD**, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin *vs* usual care in proximal-vein thrombosis patients with cancer. *Am J Med* 2006; **119**: 1062-1072 [PMID: 17145251 DOI: 10.1016/j.amjmed.2006.02.022]

67 **Lee AYY**, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin *vs* Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. *JAMA* 2015; **314**: 677-686 [PMID: 26284719 DOI: 10.1001/jama.2015.9243]

68 **Raskob GE**, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med* 2018; **378**: 615-624 [PMID: 29231094 DOI: 10.1056/NEJMoa1711948]

69 **Young AM**, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). *J Clin Oncol* 2018; **36**: 2017-2023 [PMID: 29746227 DOI: 10.1200/JCO.2018.78.8034]

70 **McBane RD 2nd**, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost* 2020; **18**: 411-421 [PMID: 31630479 DOI: 10.1111/jth.14662]

71 **Agnelli G**, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med* 2020; **382**: 1599-1607 [PMID: 32223112 DOI: 10.1056/NEJMoa1915103]

72 **Frere C**, Benzidia I, Marjanovic Z, Farge D. Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. *Cancers (Basel)* 2019; **11** [PMID: 30634638 DOI: 10.3390/cancers11010071]

73 **Carrier M**, Wang TF. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some? *Blood* 2020; **136**: 669-673 [PMID: 32575112 DOI: 10.1182/blood.2019004177]

74 **O'Connell C**, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. *Oncologist* 2021; **26**: e8-e16 [PMID: 33275319 DOI: 10.1002/onco.13584]

75 **den Exter PL**, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. *J Clin Oncol* 2011; **29**: 2405-2409 [PMID: 21555690 DOI: 10.1200/JCO.2010.34.0984]

76 **van der Hulle T**, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, Jiménez D, Portillo AK, O'Connell C, Liebman HA, Shteinberg M, Adir Y, Tiseo M, Bersanelli M, Abdel-Razeq HN, Mansour AH, Donnelly OG, Radhakrishna G, Ramasamy S, Bozas G, Maraveyas A, Shinagare AB, Hatabu H, Nishino M, Huisman MV, Klok FA. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. *J Thromb Haemost* 2016; **14**: 105-113 [PMID: 26469193 DOI: 10.1111/jth.13172]

77 **Kraaijpoel N**, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators. Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. *J Clin Oncol* 2019; **37**: 1713-1720 [PMID: 31116676 DOI: 10.1200/JCO.18.01977]

**Footnotes**

**Conflict-of-interest statement:** The author declare she has no conflict of interest relevant to the content of this paper to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 24, 2021

**First decision:** February 22, 2021

**Article in press:** April 22, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** France

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B, B, B, B, B, B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Li CG, Nari GA, Oria I, Roselli M, Tran B, Yang F **S-Editor:** Gao CC **L-Editor:** A **P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Four step adapted approach for the treatment of cancer-associated venous thromboembolism.** DOACs: Direct oral anticoagulants; UFH: Unfractionated heparin; LMWH: Low-molecular-weight heparin; CYP3A4: Cytochrome P450 3A4.

**Table 1 Studies assessing the predictive values of risk assessment models in pancreatic cancer patients**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Country** | **Patients analyzed/included** | **VTE screening at study entry** | **RAMs** | **Number of patients in each group** | **Study or median observation period** | **Patients with VTE during the overall follow-up, *n* (%)** | **Rates of VTE** |
| Pelzer *et al*[45], 2013 | Retrospective analysis of the  CONKO-004 RCT | Germany | 144/312, APC included in the CONKO-004 trial (control arm) | No | Khorana score | Intermediate risk: 55/144 (38.2%); High risk: 89/144 (61.8%) | 12 mo | 21/144 (14.6%) | At 6 mo: Intermediate risk: 4/55 (7.2%); High risk: 17/89 (19.1%) |
| Muñoz Martín *et al*[25], 2014 | Retrospective | Spain | 73/84, ambulatory PC patients  receiving chemotherapy | No | Khorana score | Intermediate risk: 36/84 (43%); High risk: 48/84 (57%) | 2008-2011 | 30/84 (35.7%) | At 6 mo: Intermediate risk: 4/37 (10.8%); High risk: 10/36 (27.8%) |
| van Es *et al*[29], 2017 | Retrospective | Netherlands | 147/178, ambulatory PC patients  starting chemotherapy | No | Khorana score | Intermediate risk: 101/147 (69%); High risk: 46/147 (31%) | 2003-2014 | 20/147(13.6%) | At 6 mo: Intermediate risk: 9/101 (8.9%); High risk: 4/46 (8.7%) |
| Kruger *et al*[28], 2017 | Retrospective | Germany | 111/172, APC patients undergoing palliative chemotherapy | No | Khorana score | Intermediate risk: 69/111 (38%); High risk: 42/111 (62%) | 2002-2012 | 16/111 (14.4%) | At 6 mo: Intermediate risk: 6/69 (8.6%)  High risk: 5/42 (11.9%); During the overall observation period; Intermediate risk: 8/69 (11.6%); High risk: 8/42 (19.0%); *P* = 0.4 |
| Berger *et al*[30], 2017 | Retrospective | Germany | 150, PC patients receiving chemotherapy | No | Khorana score | Intermediate risk: 87/150 (58%); High risk: 63/150 (42%) | 2010-2014 | 37/150 (24.7%) | Unspecified; During the overall observation period: no difference between groups (*P* = 0.44) |
| Godinho *et al*[39], 2020 | Retrospective | Portugal | 165 newly diagnosed PC patients | No | Khorana score; Onkotev score | Khorana score: Intermediate risk: 106/165 (64%); High risk: 59/165 (36%). Onkotev score: Score 0: 30/165 (18.2%); Score 1: 63/165 (38.2%); Score 2: 55/165 (33.3%); Score ≥ 3: 17/165 (10.3%) | 6.3 mo | 51/165 (31%) | During the overall observation period: Khorana score: Intermediate risk: 28/106 (26.4%); High risk: 23/59 (38.9%). Onkotev score: Score 0: 1/30 (< 10%); Score 1: 8/63 (< 10%); Score 2: 28/55 (41.8%); Score ≥ 3: 14/17 (70.6%) |
| Kim *et al*[32], 2018 | Retrospective | Korea | 216 metastatic PC patients receiving palliative chemotherapy | No | Khorana score | Intermediate risk: 135/216 (62.5%); High risk: 81/21 (37.5%) | 2005-2015 | 50/216 (23.1%) | During the overall observation period: Intermediate risk: 30/135 (22.2%); High risk: 20/81 (24.7%); *P* = 0.677 |
| Frere *et al*[34], 2020 | Prospective | France | 675 newly diagnosed PC patients | Yes, patients excluded if VTE at diagnosis | Khorana score | Intermediate risk: 492/675 (73%); High risk: 183/675 (27%) | 2014-2019; 19.3 mo | 141/675 (20.8%) | During the total follow-up: Intermediate risk: 108/492 (22%); High risk: 33/183 (18%); *P* = 0.26 |
| Vadhan-Raj *et al*[41], 2020 | Retrospective subgroup analysis of the CASSINI RCT | International | 138 PC patients undergoing chemotherapy included in the CASSINI trial (control arm) | Yes, patients excluded if VTE at diagnosis | Khorana score | Intermediate risk: 100/138 (72.5%); High risk: 38/138 (27.5%) | 6 mo | 18/138 (13.0%) | At 6 mo: Intermediate risk: 14/100 (14.0%); High risk: 4/38 (10.5%) |

APC: Advanced Pancreatic cancer; PC: Pancreatic cancer; RAM: Risk assessment model; VTE: Venous thromboembolism.

**Table 2 Studies assessing the clinical benefit of anticoagulants for the prevention of venous thromboembolism in ambulatory pancreatic cancer patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **PROTECHT** | **SAVE ONCO** | **FRAGEM** | **CONKO-0004** | **CASSINI** |
|  | Agnelli *et al*[58], 2009 | Agnelli *et al*[59], 2012 | Maraveyas *et al*[54], 2012 | Pelzer *et al*[55], 2015 | Khorana *et al*[61], 2019 and Vadhan-Raj *et al*[41], 2020 |
| Population | Ambulatory patients > 18 yr on chemotherapy with metastatic or locally advanced lung, gastrointestinal, breast, ovarian, or head and neck cancer | Patients with metastatic or locally advanced lung, pancreatic, gastric, colorectal, bladder, and ovarian cancer beginning to receive a course of chemotherapy | Patients aged 18 yr or older; Histologically/cytologically confirmed advanced or metastatic pancreatic cancer; KPS: 60-100 | Patients with histologically proven advanced pancreatic cancer were randomly assigned to ambulant first-line chemotherapy | Adult ambulatory patients with various cancers initiating a new systemic regimen and at increased risk for VTE (defined as Khorana score ≥ 2) |
| Study design | Randomized, placebo-controlled, double-blind, multicenter study | Randomized, placebo-controlled, double-blind, multicenter study | Randomized, controlled Phase 2b study | Prospective, open label, randomized, multicenter and group-sequential 2b trial | Double-blind, randomized, placebo-controlled, parallel-group, multicenter study |
| Intervention | Arm A: nadroparin 3800 IU/d; Arm B: placebo; For duration of chemotherapy (up to 4 mo maximum) | Arm A: Semuloparin, 20 mg/d; Arm B: placebo; For duration of chemotherapy (median: 3.5 mo) | Arm A: Gemcitabine + Dalteparin 200 IU/kg s.c., o.d., for 4 wk, followed by a step-down regimen to 150 IU/kg for a further 8 wk); Arm B: Gemcitabine alone; For up to 12 wk | Arm A: Enoxaparin 1 mg/kg per day; Arm B: No enoxaparin | Arm A: rivaroxaban 10 mg o.d. up to day 180; Arm B: placebo up to day 180 |
| Number of patients analyzed | Overall population: Arm A: 769 patients; Arm B: 381 patients. PC subgroup: Arm A: 36 patients; Arm B: 17 patients | Overall population: Arm A: 1608 patients; Arm B: 1604 patients. PC subgroup: Arm A: 126 patients; Arm B: 128 patients | Arm A: 59 patients; Arm B: 62 patients | Arm A: 160 patients; Arm B: 152 patients | Overall population: Arm A: 420 patients; Arm B: 404 patients. PC patients: Arm A: 135 patients; Arm B: 138 patients |
| Follow-up | 120 d | 3 mo | 3 mo | 3 mo | 6 mo |
| Thromboembolic endpoint events | Overall population: Arm A: 11/769 (1.4%); Arm B: 11/381 (2.9%); *P* = 0.02. PC subgroup: Arm A: 3/36 (8.3%); Arm B: 1/17 (5.9%); *P* = 0.755 | Overall population: Arm A:20/1608 (1.2%); Arm B: 55/1064 (1.2%); HR 0.36 (95%CI: 0.21-0.60); *P* < 0.001. PC subgroup: Arm A: 3/126 (2.4%); Arm B: 14/128 (10.9%); HR 0.22 (95%CI: 0.06-0.76); *P* = 0.015. At 3 mo: Arm A: 2/59 (3%); Arm B: 14/62 (23%); RR 0.145 (95%CI: 0.035-0.612); *P* = 0.002 | At 3 mo: Arm A: 2/160 (1.25%); Arm B: 15/152 (9.8%); HR 0.12 (95%CI: 0.03-0.52); *P* = 0.001. Entire study: Arm A: 7/59 (12%); Arm B: 17/62 (28%); RR 0.419 (95%CI: 0.187-0.935); *P* = 0.039 | Cumulative incidence rates: Arm A: 6.4%; Arm B: 15.1%; HR 0.40 (95%CI: 0.19-0.83); *P* = 0.01 | Overall population: Up-to-day-180 observation period: Arm A: 25/420 (5.95%); Arm B: 37/421 (8.79%); HR 0.66 (95%CI: 0.40-1.09); *P* = 0.101; NNT =3 5. Intervention period: Arm A: 11/420 (2.62%); Arm B: 27/421 (6.41%); HR 0.40 (95%CI: 0.20-0.80); *P* = 0.007; NNT = 26. PC subgroup: Up-to-day-180 observation period: Arm A: 13/135 (9.6%); Arm B: 18/138 (13.0%); HR 0.70 (95%CI: 0.34-1.43); *P* = 0.329. Intervention period: Arm A: 5/135 (3.7%); Arm B: 14/138 (10.1%); HR 0.35 (95%CI: 0.130-0.96); *P* = 0.043; NNT = 16 |
| Bleeding | Overall population: Major bleeding: Arm A: 5/769 (0.7%); Arm B: 0/381; *P* = 0.18. Minor bleeding: Arm A: 57/769 (7.4%); Arm B: 30/381 (7.9%); *P* = not significant. PC subgroup: *P* = not significant | Overall population: Major bleeding: Arm A: 19/1589 (1.2%); Arm B: 18/1583 (1.1%); OR 1.05 (95%CI: 0.55-2.04). CRNMB: Arm A: 26/1589 (2.8%); Arm B: 14/1583 (0.9%); OR 1.86 (95%CI: 0.98-3.68). PC subgroup: *P* = not significant | ISTH severe: Arm A: 2/59 (3%); Arm B: 2/62 (3%). ISTH non severe: Arm A: 5/59 (9%); Arm B: 2/62 (3%) | Major bleeding: Arm A: 8.3%; Arm B: 6.9%; HR 1.23 (95%CI: 0.54-2.79); *P* = 0.63 | Overall population: Major bleeding: Arm A: 8/405 (1.98%); Arm B: 4/404 (0.99%); HR 1.96 (95%CI: 0.59-6.49) *P* = 0.265; NNH = 101. CRNMB: Arm A: 2.72%; Arm B: 1.98%; HR 1.96 (95%CI: 0.59-6.49); *P* = 0.265; NNH = 101. PC subgroup: Major bleeding: Arm A: 2/130 (1.5%); Arm B: 3/131(2.3%); HR 0.67 (95%CI: 0.11-3.99); *P* = 0.654. CRNMB: Arm A: 3/131(2.3%); Arm B: 2/130 (1.5%); HR 2.47 (95%CI: 0.48-12.72); *P* = 0.264 |
| Survival | Overall population: Arm A: 33/769 (4∙3%); Arm B: 16/381 (4.2%); *P* = not significant. PC subgroup: not significant | Not significant | Arm A: 8.7 mo; Arm B: 9.7 mo | Arm A: 8.2 mo; Arm B: 8.51 mo; HR 1.01 (95%CI: 0.87-1.38); *P* = 0.44 | Overall population: All-cause mortality: Arm A: 20.0%; Arm B: 23.8%; HR 0.83 (95%CI 0.62-1.11); *P* = 0.213. PC subgroup: Arm A: 34/135 (25.2%); Arm B: 33/138 (23.9%) |

CI: Confidence interval; CRNMB: Clinically relevant non-major bleeding; HR: Hazard ratio; ISTH: International society of thrombosis and haemostasis; KPS: Karnofsky performance status; o.d.: Once daily; NTT: Number needed to treat; OR: Odds ratio; PC: Pancreatic cancer; RR: Risk ratio.

**Table 3 Randomized trials assessing the efficacy and safety of direct oral anticoagulants in cancer patients with venous thromboembolism**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HOKUSAI-CANCER VTE[68] (*n* = 1050)** | | **SELECT-D[69] (*n* = 406)** | | **ADAM-VTE[70] (*n* = 300)** | | **CARAVAGGIO[71] (*n* = 1155)** | |
|  | Edoxaban | Dalteparin | Rivaroxaban | Dalteparin | Apixaban | Dalteparin | Apixaban | Dalteparin |
| Dose | LMWH × 5 d, then 60 mg OD | 200 IU/kg × 1 mo, then 150 U/kg daily | 15 mg BID × 3 wk, then 20 mg OD × 6  mo | 200 IU/kg × 1 mo, then 150 U/kg daily | 10 mg BID × 7 d, then 5 mg BID × 6 mo | 200 IU/kg × 1 mo, then 150 U/kg daily | 10 mg BID × 7 d, then 5 mg BID × 6 mo | 200 IU/kg × 1 mo, then 150 U/kg daily |
| Patients | Patients with active cancer and symptomatic or incidental popliteal, femoral or iliac or IVC DVT, symptomatic or incidental PE | | Patients with active cancer and symptomatic DVT, symptomatic PE, or incidental PE | | Active cancer patients with acute DVT (including upper extremity), PE, splanchnic or cerebral vein thrombosis | | Patients with active or recent cancer and acute DVT or PE | |
| Primary  Endpoint | Composite of recurrent VTE/major bleeding at 12 mo | | VTE recurrence over 6 mo | | Primary safety: Major bleeding at 6mo; secondary efficacy: VTE at 6 mo | | Efficacy: Recurrent VTE at 6 mo; Safety: Major bleeding at 6 mo | |
| Follow-up | 12 mo | | 6 mo | | 6 mo | | 6 mo | |
| Recurrent VTE (%) | 41/525 (7.9) | 59/525 (11.3) | 8/203 (4) | 18/203 (11) | 1/145 (0.7) | 9/142 (6.3) | 32/576 (5.6) | 46/579 (7.9) |
| HR (95%CI) for recurrent VTE | 0.71 (0.48-1.06), *P* = 0.006 | | 0.43 (0.19-0.99) | | 0.099 (0.013-0.780), *P* = 0.03 | | 0.63 (0.37-1.07, *P* < 0.001) | |
| Major bleeding (%) | 36/525 (6.9) | 21/525 (4.0) | 11/203 (4) | 6/203 (6) | 0/145 (0) | 2/142 (1.4) | 22/576 (3.8) | 23/579 (4) |
| HR (CI) for major bleeding | 1.77 (1.03-3.04) | | 1.83 (0.68-4.96) | | Not estimable | | 0.82 (0.40-1.69, *P* = 0.6) | |
| CRNMB (%) | 76/525 (14.6) | 58/525 (11.1) | 25/203 (12.3) | 7/203 (3.4) | 9/145 (6.2) | 7/142 (4.9) | 52/576 (9) | 35/579 (6.0) |
| HR (95%CI) for CRNMB | 1.38 (0.98-1.94) | | 3.76 (1.63-8.69) | | 0.931 (0.43-2.02), *P* = 0.88 | | 1.42 (0.88-2.30) | |

DVT: Deep vein thrombosis; PE: Pulmonary embolism; VTE: Venous thromboembolism; CI: Confidence interval; CRNMB: Clinically relevant non-major bleeding; HR: Hazard ratio; LMWH: Low-molecular-weight heparin.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**